GSK's ADC Drug for Lung Cancer Gets FDA's Breakthrough Tag
The FDA bestows a Breakthrough Therapy Designation to GSK's B7-H3-targeted antibody-drug conjugate, GSK5764227, for relapsed/refractory extensive-stage small-cell lung cancer.
| Ticker |
Sentiment |
Impact |
|
BVS
|
Somewhat Bullish
|
33 %
|
|
GSK
|
Somewhat Bullish
|
50 %
|
|
ILMN
|
Somewhat Bullish
|
20 %
|
|
FULC
|
Neutral
|
27 %
|
